-
Short Sellers Shy Away from Biotech Firms
Thursday, September 13, 2012 - 1:34pm | 575Read More...The short interest data is out from the August 31 settlement date. By and large short sellers have retreated from gambles on biotech firms, compared to the August 15 settlement date. A few notable exceptions were Amgen (NASDAQ: AMGN), for which short interest was higher by 8.8 percent to 12.8...
-
Three Biotech Stocks Analysts Are Keen On (MDVN, GEVA, OPTR)
Wednesday, September 5, 2012 - 3:34pm | 581Read More...Here is a quick look three top-performing biotech stocks with a consensus recommendation of analysts of Strong Buy. They are Medivation (NASDAQ: MDVN), Synageva BioPharma (NASDAQ: GEVA) and Optimer Pharmaceuticals (NASDAQ: OPTR). Medivation This San Francisco-based biopharmaceutical company...
-
Short Interest in Biotech Firms on the Rise
Monday, August 27, 2012 - 3:21pm | 571Read More...Short interest data has been released from the August 15 settlement date. Overall short sellers have continued to bet on biotech firms compared to the July 31 settlement date. A couple of notable exceptions are Alexion Pharmaceuticals (NASDAQ: ALXN) and Biogen Idec (NASDAQ: BIIB), which saw short...
-
Short Sellers Shy Away from Biotech Firms
Monday, August 13, 2012 - 6:18am | 547Read More...The short interest data is out from the July 31 settlement date. By and large short sellers have retreated from gambles on biotech firms compared to the July 13 settlement date. A couple of notable exceptions were Dendreon (NASDAQ: DNDN), for which short interest was higher by 7 percent to 40.8...
-
Medtronic, Snyder's-Lance and Other Stocks Insiders Are Buying
Tuesday, June 26, 2012 - 10:13am | 1074Read More...Insiders may buy shares of a company because they believe its stock price will move higher and want to profit from this anticipated rise. Sell-offs might provide an opportunity for insiders who have faith in a company to snatch up shares. Below are some stocks that have recently seen insider buying...
-
Best Biotech Stocks of 2011
Tuesday, December 27, 2011 - 11:39am | 830Read More...Here's a quick look at nine of the best-performing biotech stocks of the past year. Achillion Pharmaceuticals (NASDAQ: ACHN) is up almost 88% year to date and about 37% higher just in the past month. This Connecticut-based biopharmaceutical company has three drugs in clinical trials to treat...
-
Idenix and Spectrum Pharmaceuticals to Open Near 52-Week Highs
Tuesday, November 22, 2011 - 7:49am | 364Read More...While the markets were down yesterday, news that Gilead Sciences (NASDAQ: GILD) would acquire Pharmasset (NASDAQ: VRUS) pushed some biotech stocks higher. Idenix Pharmaceuticals (NASDAQ: IDIX) and Spectrum Pharmaceuticals (NASDAQ: SPPI) reached new multiyear highs of $8.05 and $13.00 per share,...
-
UPDATE: JP Morgan Raises PT on Gilead Sciences from $45 to $50
Wednesday, July 27, 2011 - 9:53am | 126Read More...J.P. Morgan has published a research report on Gilead Sciences (NASDAQ: GILD) raising the price target. In the report, J.P. Morgan wrote, "Gilead reported solid 2Q results with non-GAAP EPS of $1.00, ahead of JPMe/cons estimates of $0.99 with total product revenues growing 11% y/y to $2.04B (cons...
-
Fifteen Health Care ETFs Trading Near 52-Week Highs
Thursday, July 21, 2011 - 1:57pm | 1271Read More...iShares Dow Jones US Healthcare Provider (NYSE: IHF) is up more than 19% year to date. The fund invests at least 90% of its assets in securities of the underlying index, which measures the performance of the health care providers sector of the U.S. equity market. Top holdings include UnitedHealth...
-
Bank of America Comments on Gilead Sciences After Research Results
Monday, July 18, 2011 - 7:11am | 214Read More...Bank of America has published a report on Gilead Sciences (NASDAQ: GILD) after HIV medication research results. In the report, Bank of America comments, "Our $43 price objective is based on 9.6x our 2012 non-GAAP EPS estimate and we believe pressures on the base business (U.S. and EU) will keep...
-
UPDATE: Piper Jaffray Upgrades Gilead Sciences to Overweight
Wednesday, June 29, 2011 - 7:31am | 129Read More...Piper Jaffray is out with its report today on Gilead Sciences (NASDAQ: GILD), upgrading GILD from Neutral to Overweight. In a note to clients, Piper Jaffray writes, "The deal with J&J for Prezista in our opinion is the first of many, with the two companies already negotiating deal for Prezista...
-
Piper Jaffray Upgrades Gilead Sciences To Overweight, Raises PT To $53
Wednesday, June 29, 2011 - 6:28am | 28Read More...Piper Jaffray has upgraded Gilead Sciences (NASDAQ: GILD) from Neutral to Overweight and has raised the price target from $42 to $53.
-
Gilead Reigns Supreme In HIV
Monday, June 6, 2011 - 8:57am | 61Read More...According to Citi, Gilead Sciences (NASDAQ: GILD) will continue to reign supreme in HIV. Citi said that it rates GILD High Risk. “While Gilead has the premier HIV franchise today, future growth depends on the continued ability of Truvada and Atripla to expand the HIV patient pool.” Gilead...
-
Deutsche Bank Comments On Gilead Sciences Client Dinner
Tuesday, May 3, 2011 - 9:01am | 140Read More...According to Deutsche Bank, it met with Gilead Sciences (NASDAQ: GILD) management. Deutsche Bank said that it hosted a client dinner with COO John Milligan last night. “Co sees B-tripla as potentially being the "kindler gentler Atripla," with potential for uptake where Sustiva is not preferred....
-
Jefferies Comments On Gilead Sciences 1Q11 Results
Thursday, April 21, 2011 - 8:22am | 90Read More...According to Jefferies, Gilead Sciences (NASDAQ: GILD) reported 1Q11 earnings that fell below its and Street expectations, with shortfalls in both the U.S. and Europe. Jefferies said that the company believes that underlying demand for its HIV drugs in both geographies are strong, and provided a...
